On October 1, 2009, the HVTN began a new clinical trial called HVTN 505.[1] HVTN 505 is a project to examine whether a particular DNA prime/boost
vaccine regimen will reduce viral load in individuals who later become infected with HIV. The experimental vaccine used in this study was developed by the Vaccine Research Center at the National Institutes of Health (NIH). Study organizers do not expect that this vaccine will prevent HIV infection and thus this vaccine is not planned for licensing, but it is expected to cause a response that will help researchers decide how to direct future vaccine trials.[2]
^ ab1970-1992. 1980 derived from AUD-USD=1.1055 and AUD-GBP=0.4957 at end of Dec 1979: 0.4957/1.1055=0.448394392; 1985 derived from AUD-USD=0.8278 and AUD-GBP=0.7130 at end of Dec 1984: 0.7130/0.8278=0.861319159
